1. Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids.
- Author
-
Kluiver TA, Lu Y, Schubert SA, Kraaier LJ, Ringnalda F, Lijnzaad P, DeMartino J, Megchelenbrink WL, Amo-Addae V, Eising S, de Faria FW, Münter D, van de Wetering M, Kerl K, Duiker E, van den Heuvel MC, de Meijer VE, de Kleine RH, Molenaar JJ, Margaritis T, Stunnenberg HG, de Krijger RR, Zsiros J, Clevers H, and Peng WC
- Subjects
- Humans, Lymphoid Enhancer-Binding Factor 1 metabolism, Lymphoid Enhancer-Binding Factor 1 genetics, beta Catenin metabolism, beta Catenin genetics, Gene Expression Regulation, Neoplastic, ErbB Receptors metabolism, ErbB Receptors genetics, Gene Regulatory Networks drug effects, Antineoplastic Agents pharmacology, Single-Cell Analysis, Hepatoblastoma genetics, Hepatoblastoma metabolism, Hepatoblastoma drug therapy, Hepatoblastoma pathology, Organoids metabolism, Organoids drug effects, Wnt Signaling Pathway drug effects, Wnt Signaling Pathway genetics, Liver Neoplasms genetics, Liver Neoplasms metabolism, Liver Neoplasms pathology, Liver Neoplasms drug therapy, Hepatocyte Nuclear Factor 4 metabolism, Hepatocyte Nuclear Factor 4 genetics
- Abstract
Hepatoblastoma, the most prevalent pediatric liver cancer, almost always carries a WNT-activating CTNNB1 mutation, yet exhibits notable molecular heterogeneity. To characterize this heterogeneity and identify novel targeted therapies, we perform comprehensive analysis of hepatoblastomas and tumor-derived organoids using single-cell RNA-seq/ATAC-seq, spatial transcriptomics, and high-throughput drug profiling. We identify two distinct tumor epithelial signatures: hepatic 'fetal' and WNT-high 'embryonal', displaying divergent WNT signaling patterns. The fetal group is enriched for liver-specific WNT targets, while the embryonal group is enriched in canonical WNT target genes. Gene regulatory network analysis reveals enrichment of regulons related to hepatic functions such as bile acid, lipid and xenobiotic metabolism in the fetal subtype but not in the embryonal subtype. In addition, the dichotomous expression pattern of the transcription factors HNF4A and LEF1 allows for a clear distinction between the fetal and embryonal tumor cells. We also perform high-throughput drug screening using patient-derived tumor organoids and identify sensitivity to HDAC inhibitors. Intriguingly, embryonal and fetal tumor organoids are sensitive to FGFR and EGFR inhibitors, respectively, indicating a dependency on EGF/FGF signaling in hepatoblastoma tumorigenesis. In summary, our data uncover the molecular and drug sensitivity landscapes of hepatoblastoma and pave the way for the development of targeted therapies., Competing Interests: Competing interests: H.C. is currently head of pharma Research Early Development (pRED) at Roche and is an inventor on several patents related to organoid technology. His full disclosure is given at www.uu.nl/staff/JCClevers . The remaining authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF